Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Hodgkin Disease 41Lymphoma 16Urinary Bladder Neoplasms 7Melanoma 6Prostatic Neoplasms 3Neoplasms 3Leukemia 3Glioma 3Carcinoma, Non-Small-Cell Lung 3Testicular Neoplasms 2Testicular Germ Cell Tumor 2Skin Neoplasms 2Lymphoma, Large-Cell, Anaplastic 2Central Nervous System Neoplasms 2Breast Neoplasms 2Brain Neoplasms 2Astrocytoma 2Urothelial Carcinoma of the Bladder 1Urethral Neoplasms 1Ureteral Neoplasms 1Teratoma 1Survival Without Progression 1Seminoma 1Rhabdoid Tumor 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Pathologic Complete Response 1Oligodendroglioma 1Neurofibromatosis 1 1

Interventions

pembrolizumab 2enfortumab vedotin 2Gemcitabine 2Cisplatin 2sacituzumab govitecan 1erdafitinib 1avelumab 1Vinblastine 1Paclitaxel 1Nivolumab 1Methotrexate 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Muscle Invasive Bladder Urothelial Carcinoma × Vinblastine × Clear all
NCT06204614 2026-05-18

Drug Screening Using IMD in Bladder Cancer

Brigham and Women's Hospital

Phase EARLY_PHASE1 Enrolling by invitation
18 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡